Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
Enhancing Solid Tumor Immunotherapy: TCR-pMHC Interactions in CAR T-cells
FY 2024-25
Summary
Our study aims to enhance immunotherapy strategies for solid tumors by exploring the role of TCR-pMHC interactions across different therapeutic modalities, including Chimeric Antigen Receptor (CAR) T-cells and Immune Checkpoint Inhibitors (ICIs). While CAR T-cells directly target tumor antigens via synthetic receptors, ICIs and cancer vaccines rely on TCR-mediated recognition of tumor-specific neoantigens presented by the major histocompatibility complex (pMHC). Findings from clinical trials, including our recent first-in-person testing of a novel CAR T-cell therapy (GCAR1) for alveolar soft-part sarcoma, suggest that CAR T-cell therapy may also activate endogenous tumor-reactive T-cells, highlighting potential synergy between CAR T-cell activity and endogenous TCR-pMHC responses. This research will focus on identifying tumor-specific antigen repertoires, evaluating their MHC binding, and characterizing pMHC-specific T-cells in patients with poor-prognosis solid tumors. Leveraging unique resources developed in the context of ICI treatments and in our ongoing GCAR1 CAR T-cell trial, including patient blood samples collected serially throughout treatment, and access to GCAR1 clinical products, we will use genomic, transcriptomic, and immunopeptidomic analyses to validate neoantigen predictions and assess TCR engagement in peripheral blood, and when applicable, on CAR-positive and negative GCAR1 T-cells. This strategy will delineate the role of endogenous immunity in CAR T-cell therapies, providing deeper insight into opportunities for rational combinations of CAR T-cell therapies with ICIs, and/or cancer vaccine approaches.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530013
Name
Gilbert Geneece
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Solid Tumor Immunotherapy: TCR-pMHC Interactions in CAR T-cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Vaccine; Chimeric Antigen Receptor T-Cell; Genomics; Immune Checkpoint Blockade; Immunopeptidomics; Immunotherapy; Major Histocompatibility Complex; T-Cell Receptor; Transcriptomics; Tumor Specific Antigen
Abstract
Our study aims to enhance immunotherapy strategies for solid tumors by exploring the role of TCR-pMHC interactions across different therapeutic modalities, including Chimeric Antigen Receptor (CAR) T-cells and Immune Checkpoint Inhibitors (ICIs). While CAR T-cells directly target tumor antigens via synthetic receptors, ICIs and cancer vaccines rely on TCR-mediated recognition of tumor-specific neoantigens presented by the major histocompatibility complex (pMHC). Findings from clinical trials, including our recent first-in-person testing of a novel CAR T-cell therapy (GCAR1) for alveolar soft-part sarcoma, suggest that CAR T-cell therapy may also activate endogenous tumor-reactive T-cells, highlighting potential synergy between CAR T-cell activity and endogenous TCR-pMHC responses. This research will focus on identifying tumor-specific antigen repertoires, evaluating their MHC binding, and characterizing pMHC-specific T-cells in patients with poor-prognosis solid tumors. Leveraging unique resources developed in the context of ICI treatments and in our ongoing GCAR1 CAR T-cell trial, including patient blood samples collected serially throughout treatment, and access to GCAR1 clinical products, we will use genomic, transcriptomic, and immunopeptidomic analyses to validate neoantigen predictions and assess TCR engagement in peripheral blood, and when applicable, on CAR-positive and negative GCAR1 T-cells. This strategy will delineate the role of endogenous immunity in CAR T-cell therapies, providing deeper insight into opportunities for rational combinations of CAR T-cell therapies with ICIs, and/or cancer vaccine approaches.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gilbert, Geneece
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~